Clinical Trial: A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Triple Negative Breast Cancer
Study Type: INTERVENTIONAL
Official Title: A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
Brief Summary:
The purpose of this study is to assess the safety, tolerability and efficacy of the study drug AO-252 and identify the best dose for use in future studies.
Read more